Introduction
Tirzepatide is a synthetic dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. As the first member of the ‘twincretin’ class of research peptides, Tirzepatide offers a unique pharmacological profile that has generated significant interest in metabolic, cardiovascular, and adipose tissue biology research.
For research and laboratory use only. Not intended for human or veterinary administration.
Molecular Structure
Tirzepatide is a 39-amino acid peptide based on the native GIP sequence, with modifications to enable dual receptor activity and extended half-life:
- GIP-based backbone: The peptide sequence is derived from native GIP(1-39), providing primary GIP receptor affinity.
- GLP-1 receptor activity: Specific amino acid substitutions confer potent GLP-1 receptor agonism alongside GIP receptor activity.
- C20 fatty diacid chain: Attached via a linker to enable albumin binding, extending the half-life to approximately 5 days.
- Aib substitutions: Multiple alpha-aminoisobutyric acid substitutions confer DPP-4 resistance.
Dual Receptor Pharmacology
GIP Receptor (GIPR)
The GIP receptor is a class B GPCR expressed in pancreatic beta and alpha cells, adipose tissue, bone, and the central nervous system. GIP receptor activation promotes:
- Glucose-dependent insulin secretion (synergistic with GLP-1R activation)
- Glucagon secretion at low glucose concentrations (unlike GLP-1)
- Lipid uptake and storage in adipose tissue
- Bone formation and reduced resorption
GLP-1 Receptor (GLP-1R)
As described in the GLP-1 research overview, GLP-1R activation promotes insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic appetite suppression.
Synergistic ‘Twincretin’ Effects
Research suggests that simultaneous activation of both GIPR and GLP-1R produces effects greater than either agonist alone. Proposed mechanisms include:
- Complementary cAMP signalling in beta cells leading to enhanced insulin secretion
- GIPR-mediated sensitisation of adipose tissue to GLP-1R-driven lipolysis
- Central nervous system co-activation producing additive appetite suppression
- Differential effects on glucagon that may improve postprandial glucose control
Metabolic Research Applications
- Obesity models: Superior body weight reduction compared to selective GLP-1 agonists in preclinical dose-response studies.
- Glycaemic control: Enhanced insulin secretion and improved beta-cell function in type 2 diabetes models.
- Adipose tissue biology: Investigation of GIPR-mediated effects on adipocyte function, lipid metabolism, and adipokine secretion.
- NASH/NAFLD: Hepatic steatosis and inflammation reduction in diet-induced liver disease models.
- Bone metabolism: GIPR expression in osteoblasts and osteoclasts makes Tirzepatide of interest in bone biology research.
Cardiovascular Research
Emerging preclinical research has investigated Tirzepatide’s effects on:
- Atherosclerosis progression in hyperlipidaemic models
- Cardiac function and myocardial energy metabolism
- Blood pressure and vascular inflammation markers
- Heart failure models — particularly in the context of obesity-related cardiomyopathy
Available Concentrations for Research
Vanta Labs supplies Tirzepatide across a wide concentration range to support dose-response, chronic dosing, and comparative studies: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 90 mg, 100 mg, and 120 mg.
Storage and Handling
Store lyophilised Tirzepatide at −20°C, protected from light and moisture. Reconstitute with bacteriostatic water. Once reconstituted, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles and agitation.
All products supplied by Vanta Labs are intended strictly for laboratory and research purposes.